Teva Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 3/6
Teva Pharmaceutical Industries has a total shareholder equity of $8.1B and total debt of $19.8B, which brings its debt-to-equity ratio to 244.1%. Its total assets and total liabilities are $43.5B and $35.4B respectively. Teva Pharmaceutical Industries's EBIT is $3.2B making its interest coverage ratio 3.3. It has cash and short-term investments of $3.2B.
Key information
244.1%
Debt to equity ratio
US$19.83b
Debt
Interest coverage ratio | 3.3x |
Cash | US$3.23b |
Equity | US$8.13b |
Total liabilities | US$35.35b |
Total assets | US$43.48b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TEVA's short term assets ($12.5B) exceed its short term liabilities ($12.2B).
Long Term Liabilities: TEVA's short term assets ($12.5B) do not cover its long term liabilities ($23.1B).
Debt to Equity History and Analysis
Debt Level: TEVA's net debt to equity ratio (204.4%) is considered high.
Reducing Debt: TEVA's debt to equity ratio has increased from 183.1% to 244.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TEVA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TEVA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 21.5% per year.